Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Clearmind Medicine Inc. (CMND : NSDQ)

• Company Description    Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Clearmind Medicine Inc. is based in VANCOUVER. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $2.26 Daily Weekly Monthly 20 Day Moving Average: 444,333 shares Shares Outstanding: 1.02 (millions) Market Capitalization: $2.30 (millions) Beta: 0.87 52 Week High: $524.00 52 Week Low: $2.10 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -72.37% -73.72% 12 Week -80.35% -81.83% Year To Date -87.51% -87.50%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 101-1220 WEST 6TH AVENUE - VANCOUVER,A1 V6H1A5 CAN ph: 973-536-1016 fax: - invest@clearmindmedicine.com http://www.clearmindmedicine.com

• General Corporate Information    Officers Adi Zuloff-Shani - Chief Executive Officer Amitay Weiss - Chairman of the Board of Director Alan Rootenberg - Chief Financial Officer Yehonatan Shachar - Director Oz Adler - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 185053600 SIC: 2834 Fiscal Year Fiscal Year End: October Last Reported Quarter: 01/01/26 Next Expected EPS Date: 06/11/26 Share - Related Items Shares Outstanding: 1.02 Most Recent Split Date: 5.00 (0.10:1) Beta: 0.87 Market Capitalization: $2.30 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 06/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.04 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 65.42% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 04/30/26 - - 01/31/26 - -207.53 10/31/25 - -208.09 ROA 04/30/26 - - 01/31/26 - -100.70 10/31/25 - -70.71 Current Ratio 04/30/26 - - 01/31/26 - 3.79 10/31/25 - 1.22 Quick Ratio 04/30/26 - - 01/31/26 - 3.79 10/31/25 - 1.22 Operating Margin 04/30/26 - - 01/31/26 - - 10/31/25 - - Net Margin 04/30/26 - - 01/31/26 - - 10/31/25 - - Pre-Tax Margin 04/30/26 - - 01/31/26 - - 10/31/25 - - Book Value 04/30/26 - - 01/31/26 - 54.93 10/31/25 - 14.41 Inventory Turnover 04/30/26 - - 01/31/26 - - 10/31/25 - - Debt-to-Equity 04/30/26 - - 01/31/26 - 0.00 10/31/25 - 0.00 Debt-to-Capital 04/30/26 - - 01/31/26 - 0.00 10/31/25 - 0.00

Powered by Zacks Investment Research ©